Am J Transplant, Volume 22, Suppl 3 Archives - Page 169 of 190 - ATC Abstracts

2022 American Transplant Congress
Outcomes of Kidney Transplantation from a Male Donor with a Highly Elevated Prostate Specific Antigen Level (PSA) in Female Recipients
S. K. Patel, E. Siskind, M. Jaleco, S. Shah, A. Adekile, S. Nijim, M. Laftavi
Center for Transplantation, University Medical Center of Southern Nevada, Las Vegas, NV
*Purpose: Donor derived malignancy is a contraindication for kidney transplantation. Published literature is devoid of instances of utilization of organs from donors with high PSA…
2022 American Transplant Congress
Cardiovascular Outcomes of Kidney Transplant Recipients Receiving Belatacept Compared to a Matched Tacrolimus
Y. Kim¹, J. Marvin¹, K. Belfield¹, G. Girone¹, R. Formica², E. Cohen¹
¹Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Tacrolimus (TAC), a calcineurin inhibitor (CNI), is the backbone of maintenance immunosuppression in kidney transplant recipients (KTR) but has been associated with cardiovascular (CV)…
2022 American Transplant Congress
Adding Epitope Compatibility To Deceased Donor Kidney Allocation Criteria: Recommendations From An Online Public Deliberation
L. Edwards¹, R. Sapir-Pichhadze², P. Keown³, S. Bryan¹
¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²McGill University, Montreal, QC, Canada, ³Department of Medicine, University of British Columbia, Vancouver, BC, Canada
*Purpose: With increasing demand for kidneys and a scarce supply, ways to reduce rejection and improve transplant outcomes are needed. One possibility is using epitope…
2022 American Transplant Congress
Early Clinical Experience With Alvr109, A Partially Hla-matched Sars-cov-2 Specific T-cell Therapy, In Immunocompromised Patients With Covid-19
G. Haidar¹, J. Jacobs², K. Hughes², K. McCormick², A. Naqvi², M. Agha², T. Bogdanovich², B. Johnson², J. Kozar², E. Lendermon², C. Marino², A. Raptis², F. Silveira², W. Marshall³, M. Miller³, E. Atillasoy³, J. Mellors²
¹University of Pittsburgh, Pittsburgh, PA, ²UPitt, Pittsburgh, PA, ³Allovir, Waltham, MA
*Purpose: Therapies for COVID-19 in immunocompromised (IC) patients (pts), including transplant (tx) pts, are limited. We describe our experience with ALVR109, an allogeneic, partially HLA-matched…
2022 American Transplant Congress
In Vitro Fertilization Use Among Female Kidney Transplant Recipients
L. A. Coscia¹, J. M. Konel², M. Bowring³, S. Constantinescu⁴, M. J. Moritz⁵
¹Transplant Pregnancy Registry International, Philadelphia, PA, ²Wayne State University School of Medicine, Detroit, MI, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ⁵Surgery, Lehigh Valley Health Network, Allentown, PA
*Purpose: Infertility is common among female kidney transplant recipients (KTRs). In vitro fertilization (IVF) is a potential option. The purpose of this study was to…
2022 American Transplant Congress
Increased Regulatory T-cells in Tumor Microenvironment is Associated with Hepatocellular Carcinoma Differentiation in Patients Undergoing Liver Transplantation
G. Orozco¹, R. Gedaly², L. Turcios², F. Marti²
¹Surgery, University of Kentucky, Lexington, KY, ²UKHC, Lexington, KY
*Purpose: Tumor-infiltrating lymphocytes are an essential component of the tumor microenvironment. The balance between cytotoxic effector T cells and immunosuppressive regulatory T cells is critical…
2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir versus Valganciclovir for CMV Prophylaxis: A Randomized Controlled Trial
P. S. Verghese¹, A. Matas², S. Chinnakotla², M. Evans³, H. Balfour Jr⁴
¹Univ of Minnesota Pediatric Nephrology, Minneapolis, MN, ²Surgery, University of Minnesota Medical School, Minneapolis, MN, ³Biostatistics, University of Minnesota, Minneapolis, MN, ⁴Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
*Purpose: Valganciclovir (valG) is an effective CMV prophylactic agent post-kidney transplant (KTx) with significant side effects. Valacyclovir (valA) may be effective for CMV prophylaxis with…
2022 American Transplant Congress
Prevalence and Clinical Significance of Pancreatic Cystic Lesions in Immunosuppressed Patients with Solid Organ Transplantation
Y. Yu, H. Jo, Y. Choi, J. Lee, D. Kim
HBP surgery and liver transplantation, Korea University College of Medicine and School of Medicine, Seoul, Korea, Republic of
*Purpose: Solid organ transplant recipients have an increased risk of cancer due to immunosuppressive therapy. Pancreatic cystic lesions (PCLs) are increasingly being detected, some with…
2022 American Transplant Congress
First-in-Human Clinical-Grade Porcine Kidney Xenotransplant
J. E. Locke¹, B. Orandi¹, V. Kumar¹, J. Houp¹, D. Anderson¹, V. Hauptfeld¹, D. Martin², C. Killian¹, S. Macedon¹, N. Budd¹, K. Stegner¹, A. Dandro³, M. Kokkinaki³, K. Kuravi³, R. Reed⁴, H. Fatima¹, G. Baker¹, J. Perry¹, E. Bryant¹, M. Cheung¹, E. Erman¹, K. Kraebber¹, T. Gamblin¹, L. Guy¹, D. Ayares³, P. Porrett¹
¹University of Alabama at Birmingham, Birmingham, AL, ²Deakin University, Geelong, Australia, ³Revivicor, Incorporated, Blacksburg, VA, ⁴University of Alabama at Birmingham, Irondale, AL
*Purpose: Proof-of-concept xenotransplant work has been performed in pig to non-human primates (NHP), but it is unclear if outcomes can be recapitulated in humans. While…
2022 American Transplant Congress
The Post-operative Clinical Outcomes Of 59 Tanrp Cases In An International Cohort
J. Louca¹, N. Patel¹, S. Messer², J. Chindu², S. Large²
¹Cambridge University, Cambridge, United Kingdom, ²Royal Papworth Hospital, Cambridge, United Kingdom
*Purpose: Heart transplantation is an immensely effective service and is currently the only definitive treatment for heart failure. However, transplantation is limited by donor availability.…